Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting.

Deeb LC, Dulude H, Guzman CB, Zhang S, Reiner BJ, Piché CA, Pradhan S, Zhang XM.

Pediatr Diabetes. 2018 Aug;19(5):1007-1013. doi: 10.1111/pedi.12668. Epub 2018 Mar 22.

PMID:
29512902
2.

Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting.

Seaquist ER, Dulude H, Zhang XM, Rabasa-Lhoret R, Tsoukas GM, Conway JR, Weisnagel SJ, Gerety G, Woo VC, Zhang S, Carballo D, Pradhan S, Piché CA, Guzman CB.

Diabetes Obes Metab. 2018 May;20(5):1316-1320. doi: 10.1111/dom.13278. Epub 2018 Mar 22.

3.

Faster Use and Fewer Failures with Needle-Free Nasal Glucagon Versus Injectable Glucagon in Severe Hypoglycemia Rescue: A Simulation Study.

Yale JF, Dulude H, Egeth M, Piché CA, Lafontaine M, Carballo D, Margolies R, Dissinger E, Shames AR, Kaplowitz N, Zhang MX, Zhang S, Guzman CB.

Diabetes Technol Ther. 2017 Jul;19(7):423-432. doi: 10.1089/dia.2016.0460. Epub 2017 May 30.

4.

Response to Comment on Rickels et al. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. Diabetes Care 2016;39:264-270.

Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, Haller MJ, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW; T1D Exchange Intranasal Glucagon Investigators.

Diabetes Care. 2016 Oct;39(10):e193-4. doi: 10.2337/dci16-0025. No abstract available.

5.

Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes.

Sherr JL, Ruedy KJ, Foster NC, Piché CA, Dulude H, Rickels MR, Tamborlane WV, Bethin KE, DiMeglio LA, Fox LA, Wadwa RP, Schatz DA, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW; T1D Exchange Intranasal Glucagon Investigators.

Diabetes Care. 2016 Apr;39(4):555-62. doi: 10.2337/dc15-1606. Epub 2016 Feb 16.

6.

Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.

Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, Haller MJ, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW; T1D Exchange Intranasal Glucagon Investigators.

Diabetes Care. 2016 Feb;39(2):264-70. doi: 10.2337/dc15-1498. Epub 2015 Dec 17.

7.

Urodynamic parameters and plasma LH/FSH in spayed Beagle bitches before and 8 weeks after GnRH depot analogue treatment.

Reichler IM, Barth A, Piché CA, Jöchle W, Roos M, Hubler M, Arnold S.

Theriogenology. 2006 Dec;66(9):2127-36. Epub 2006 Jul 31.

PMID:
16876857
8.
9.

Clinical and endocrine responses to treatment with deslorelin acetate implants in ferrets with adrenocortical disease.

Wagner RA, Piché CA, Jöchle W, Oliver JW.

Am J Vet Res. 2005 May;66(5):910-4.

PMID:
15934621
10.

PEGylated insulin in PLGA microparticles. In vivo and in vitro analysis.

Hinds KD, Campbell KM, Holland KM, Lewis DH, Piché CA, Schmidt PG.

J Control Release. 2005 Jun 2;104(3):447-60.

PMID:
15911045
11.

FSH and LH plasma levels in bitches with differences in risk for urinary incontinence.

Reichler IM, Hung E, Jöchle W, Piché CA, Roos M, Hubler M, Arnold S.

Theriogenology. 2005 May;63(8):2164-80.

PMID:
15826681
12.

Changes in plasma gonadotropin concentrations and urethral closure pressure in the bitch during the 12 months following ovariectomy.

Reichler IM, Pfeiffer E, Piché CA, Jöchle W, Roos M, Hubler M, Arnold S.

Theriogenology. 2004 Nov;62(8):1391-402.

PMID:
15451248
13.

Long-term delivery of ivermectin by use of poly(D,L-lactic-co-glycolic)acid microparticles in dogs.

Clark SL, Crowley AJ, Schmidt PG, Donoghue AR, Piché CA.

Am J Vet Res. 2004 Jun;65(6):752-7.

PMID:
15198214
14.

2-hydroxyestradiol is a prodrug of 2-methoxyestradiol.

Zacharia LC, Piché CA, Fielding RM, Holland KM, Allison SD, Dubey RK, Jackson EK.

J Pharmacol Exp Ther. 2004 Jun;309(3):1093-7. Epub 2004 Feb 10.

PMID:
14872091
15.

The effect of GnRH analogs on urinary incontinence after ablation of the ovaries in dogs.

Reichler IM, Hubler M, Jöchle W, Trigg TE, Piché CA, Arnold S.

Theriogenology. 2003 Oct 15;60(7):1207-16.

PMID:
14511775
16.

Effect of antiparasitic treatment in beef replacement heifers.

Bauck SW, Piche CA, Newcomb KM.

Can Vet J. 1992 Jun;33(6):394-6.

17.

Comparison of ivermectin, oxibendazole, and pyrantel pamoate in suppressing fecal egg output in horses.

Piché CA, Kennedy MJ, Herbers HA, Newcomb KM.

Can Vet J. 1991 Feb;32(2):104-7.

18.

Comparison of three anthelmintics in the control of intestinal nematodes in young horses on fall and winter pasture.

Piché CA, Kennedy MJ, Bauck SW, Goonewardene L.

Can Vet J. 1990 Dec;31(12):841-3. No abstract available.

19.

Benzimidazole resistance in horses in western Canada.

Piché CA, Kennedy MJ, Bauck S.

Can Vet J. 1989 Feb;30(2):173-4. No abstract available.

20.

Clinical observations on an outbreak of strangles.

Piché CA.

Can Vet J. 1984 Jan;25(1):7-11.

Supplemental Content

Loading ...
Support Center